PROFESSIONAL CONTINUOUS GLUCOSE MONITORING (CGM)

iPro®2
Professional CGM

CREATES A 6-DAY GLUCOSE PROFILE:
Continuously measures glucose levels for a 6-day period

IDENTIFIES GLUCOSE VARIABILITY:
Uncovers hidden hypoglycemic/hyperglycemic events

UNCOVER MORE IN LESS TIME:
Connect patient behavior to highs and lows with easy-to-understand reports

HIGHLY ACCURATE & SIMPLE
Proven Medtronic Technology

EASY TO **START**

EASY TO **WEAR**

EASY TO **USE**

Patient setup in minutes:
1. Insert sensor
2. Educate patient
3. Go about everyday life

iPro2 CGM:
- Small, lightweight and discreet
- Blinded data - no alerts
- Watertight*

CareLink® iPro software:
- Downloads easily and works with over a dozen compatible meters
- Provides key information at a glance to help make adjustments timely and effective
- Includes easy-to-understand reports connecting patient behavior to highs and lows

WHO DOES PROFESSIONAL CGM HELP?
According to the AACE consensus statement,† patients with diabetes (type 1 or type 2) can benefit from professional CGM if they exhibit any of the following:

- Are not at their A1C target with excess glycemic variability
- Experience recurrent hypoglycemia or hypoglycemic unawareness
- Require A1C lowering without increased hypoglycemia
- Have had changes to their diabetes regimen

Call your Medtronic Diabetes rep for more information

* The iPro2 and sensor are watertight for up to 30 minutes, up to a depth of 8 feet (2.4 meters). There is no time limit for swimming on the surface of the water or showering. Refer to the iPro2 User Guide for further details.
**Analysis based on published medical coverage policies on file. Coverage policies may be subject to medical necessity, place of service, provider restrictions and patient coverage criteria as outlined by health plan policies. Not a statement of coverage. Providers must verify coverage, coding and payment with individual health plans.
¥ Medicare Coverage Analysis based on Medicare Archive of Retired Medicare Policies. CMS Archive LCD Determination ID: L31165 version 11.
Δ Current Procedural Terminology ©2016 American Medical Association. All Rights Reserved
∞ Medicare payment amounts based on 2016 Medicare Physician Fee Schedule. CMS National Average Allowable for the Physician's Office Setting when performed by a physician. Amounts include patient out of pocket responsibility.
† AACE consensus statement

Medtronic

PROFESSIONAL CONTINUOUS GLUCOSE MONITORING (CGM)

iPro2 Professional CGM

Why Use Professional CGM? Why is CGM Important?

>50% OF ALL PATIENTS
ACROSS THE TYPE 2 CONTINUUM OF CARE ARE IN POOR CONTROL[1]

93% OF HYPOGLYCEMIC EPISODES
WERE UNRECOGNIZED BY BLOOD GLUCOSE METER OR SYMPTOMS[2]

CGM vs Fingerstick Glucose Readings





Pattern Snapshot Report:

Provides key information at a glance to make therapy adjustments timely and effective

iPRO2 CGM IS PROVEN TO HELP LOWER A1C WITHOUT THE RISK OF HYPOGLYCEMIA[3]

iPRO2 CGM CAN REVEAL OVER FOUR TIMES MORE GLUCOSE FLUCTUATIONS THAN SELF-MONITORING BLOOD GLUCOSE ALONE[4]

USE OF iPRO2 CGM CAN REDUCE THE LENGTH OF HYPOGLYCEMIC EVENTS COMPARED WITH SELF-MONITORING BLOOD GLUCOSE ALONE[5]

Important Safety Information
The iPro2 digital recorder is intended to continuously record interstitial glucose levels in persons with diabetes mellitus. This information is intended to supplement, not replace, blood glucose information obtained using standard home glucose monitoring devices. The information collected by the iPro2 digital recorder may be uploaded to a computer (with Internet access) and reviewed by healthcare professionals. The information may allow identification of patterns of glucose-level excursions above and below a desired range, facilitating therapy adjustments, which may minimize these excursions. This iPro2 system: s intended for prescription use only. For additional details, please see http://www.medtronicdiabetes.com/support/download-library/user-guides and www.medtronicdiabetes.com/importantsafetyinformation.

1. Harris MI. Eastman RC. Cowie CC. Flegal KM. Eberhardt MS. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. *Diabetes Care.* 1999i22II).403-8
2. Munshi M. et al. Frequent Hypoglycemia Among Elderly Patients With Poor Glycemic Control. *Arch Intern Med.* 2011;171(4):362-4.
3. Chase HP. Kim LM. Owen SL. et al. Continuous subcutaneous glucose monitoring in children with type 1 diabetes. *Pediatrics.* 2001;107(2):222–227.
4. Kaufman FR. Gibson LC. Halvorson M. et al. A pilot study of the contiruous glucose monitoring system: clinical decisions and glycemic control after its use in pediatric type 1 diabetic subjects. *Diabetes Care.* 2001:24(12):2030-4
5. Tanenberg R. Bode B. Lane W. et al. Use of the Continuous Glucose Monitoring System to guide therapy in patients with insulin-treated diabetes,: a randomized controlled trial. *Mayo Clin Proc.* 2004:79(12): 1521-6

Medtronic